Get startedLog in
    Picture of Cereno Scientific AB logo

    CRNO B — Cereno Scientific AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapSucker Stock
    All News

    Brief: Cereno Announces Positive Results From Phase I Trial Of Cs014

    Picture of Cereno Scientific AB logoCereno Scientific AB
    15/07/2025 13:03
    July 15 (Reuters) - Cereno Scientific AB CRNOSb.ST:

CERENO SCIENTIFIC ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE I TRIAL OF CS014 - A NOVEL HDAC INHIBITOR - SUPPORTING ADVANCEMENT INTO PHASE II

TRIAL CONFIRMS A FAVORABLE SAFETY AND TOLERABILITY PROFILE, AND DATA SUPPORT FURTHER CLINICAL EVALUATION.

PREPARATIONS ARE UNDERWAY TO INITIATE A PHASE II TRIAL.

CS014 WAS WELL-TOLERATED AND SHOWED FAVORABLE SAFETY IN HEALTHY VOLUNTEERS

Source text: ID:nWkr76G8kn

Further company coverage: [CRNOSb.ST]

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))

    Recent news on Cereno Scientific AB

    See all news